FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2626716901> ?p ?o ?g. }

• W2626716901 endingPage "1083" @default.
• W2626716901 startingPage "1083" @default.
• W2626716901 abstract "<h3>Importance</h3> Achieving linkage to care and viral suppression in human immunodeficiency virus (HIV)-positive patients improves their well-being and prevents new infections. Current gaps in the HIV care continuum substantially limit such benefits. <h3>Objective</h3> To evaluate the effectiveness of financial incentives on linkage to care and viral suppression in HIV-positive patients. <h3>Design, Setting, and Participants</h3> A large community-based clinical trial that randomized 37 HIV test and 39 HIV care sites in the Bronx, New York, and Washington, DC, to financial incentives or standard of care. <h3>Interventions</h3> Participants at financial incentive test sites who had positive test results for HIV received coupons redeemable for $125 cash-equivalent gift cards upon linkage to care. HIV-positive patients receiving antiretroviral therapy at financial incentive care sites received $70 gift cards quarterly, if virally suppressed. <h3>Main Outcomes and Measures</h3> Linkage to care: proportion of HIV-positive persons at the test site who linked to care within 3 months, as indicated by CD4⁺and/or viral load test results done at a care site. Viral suppression: proportion of established patients at HIV care sites with suppressed viral load (<400 copies/mL), assessed at each calendar quarter. Outcomes assessed through laboratory test results reported to the National HIV Surveillance System. <h3>Results</h3> A total of 1061 coupons were dispensed for linkage to care at 18 financial incentive test sites and 39 359 gift cards were dispensed to 9641 HIV-positive patients eligible for gift cards at 17 financial incentive care sites. Financial incentives did not increase linkage to care (adjusted odds ratio, 1.10; 95% CI, 0.73-1.67;<i>P</i> = .65). However, financial incentives significantly increased viral suppression. The overall proportion of patients with viral suppression was 3.8% higher (95% CI, 0.7%-6.8%;<i>P</i> = .01) at financial incentive sites compared with standard of care sites. Among patients not previously consistently virally suppressed, the proportion virally suppressed was 4.9% higher (95% CI, 1.4%-8.5%;<i>P</i> = .007) at financial incentive sites. In addition, continuity in care was 8.7% higher (95% CI, 4.2%-13.2%;<i>P</i> < .001) at financial incentive sites. <h3>Conclusions and Relevance</h3> Financial incentives, as used in this study (HPTN 065), significantly increased viral suppression and regular clinic attendance among HIV-positive patients in care. No effect was noted on linkage to care. Financial incentives offer promise for improving adherence to treatment and viral suppression among HIV-positive patients. <h3>Trial Registration</h3> clinicaltrials.gov Identifier:NCT01152918" @default.
• W2626716901 created "2017-06-23" @default.
• W2626716901 creator A5004079054 @default.
• W2626716901 creator A5010009356 @default.
• W2626716901 creator A5015651591 @default.
• W2626716901 creator A5018723471 @default.
• W2626716901 creator A5027160485 @default.
• W2626716901 creator A5032860493 @default.
• W2626716901 creator A5039768655 @default.
• W2626716901 creator A5043989399 @default.
• W2626716901 creator A5045762100 @default.
• W2626716901 creator A5055366972 @default.
• W2626716901 creator A5060445377 @default.
• W2626716901 creator A5063945368 @default.
• W2626716901 creator A5065911353 @default.
• W2626716901 creator A5066252006 @default.
• W2626716901 creator A5072414228 @default.
• W2626716901 creator A5079366973 @default.
• W2626716901 date "2017-08-01" @default.
• W2626716901 modified "2023-10-16" @default.
• W2626716901 title "Financial Incentives for Linkage to Care and Viral Suppression Among HIV-Positive Patients" @default.
• W2626716901 cites W1987573857 @default.
• W2626716901 cites W2002945998 @default.
• W2626716901 cites W2020285227 @default.
• W2626716901 cites W2036408211 @default.
• W2626716901 cites W2044369525 @default.
• W2626716901 cites W2065962849 @default.
• W2626716901 cites W2069258149 @default.
• W2626716901 cites W2075548855 @default.
• W2626716901 cites W2079766092 @default.
• W2626716901 cites W2082540690 @default.
• W2626716901 cites W2104015227 @default.
• W2626716901 cites W2112703815 @default.
• W2626716901 cites W2114990707 @default.
• W2626716901 cites W2124936170 @default.
• W2626716901 cites W2127832030 @default.
• W2626716901 cites W2148024683 @default.
• W2626716901 cites W2149443374 @default.
• W2626716901 cites W2152505869 @default.
• W2626716901 cites W2153244256 @default.
• W2626716901 cites W2159612600 @default.
• W2626716901 cites W2170138433 @default.
• W2626716901 cites W2238552371 @default.
• W2626716901 cites W2315459740 @default.
• W2626716901 cites W2323766141 @default.
• W2626716901 cites W2393834324 @default.
• W2626716901 cites W2412012985 @default.
• W2626716901 cites W2461496717 @default.
• W2626716901 cites W2467253582 @default.
• W2626716901 cites W2545148820 @default.
• W2626716901 cites W2586911529 @default.
• W2626716901 cites W4250901970 @default.
• W2626716901 doi "https://doi.org/10.1001/jamainternmed.2017.2158" @default.
• W2626716901 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5604092" @default.
• W2626716901 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28628702" @default.
• W2626716901 hasPublicationYear "2017" @default.
• W2626716901 type Work @default.
• W2626716901 sameAs 2626716901 @default.
• W2626716901 citedByCount "99" @default.
• W2626716901 countsByYear W26267169012017 @default.
• W2626716901 countsByYear W26267169012018 @default.
• W2626716901 countsByYear W26267169012019 @default.
• W2626716901 countsByYear W26267169012020 @default.
• W2626716901 countsByYear W26267169012021 @default.
• W2626716901 countsByYear W26267169012022 @default.
• W2626716901 countsByYear W26267169012023 @default.
• W2626716901 crossrefType "journal-article" @default.
• W2626716901 hasAuthorship W2626716901A5004079054 @default.
• W2626716901 hasAuthorship W2626716901A5010009356 @default.
• W2626716901 hasAuthorship W2626716901A5015651591 @default.
• W2626716901 hasAuthorship W2626716901A5018723471 @default.
• W2626716901 hasAuthorship W2626716901A5027160485 @default.
• W2626716901 hasAuthorship W2626716901A5032860493 @default.
• W2626716901 hasAuthorship W2626716901A5039768655 @default.
• W2626716901 hasAuthorship W2626716901A5043989399 @default.
• W2626716901 hasAuthorship W2626716901A5045762100 @default.
• W2626716901 hasAuthorship W2626716901A5055366972 @default.
• W2626716901 hasAuthorship W2626716901A5060445377 @default.
• W2626716901 hasAuthorship W2626716901A5063945368 @default.
• W2626716901 hasAuthorship W2626716901A5065911353 @default.
• W2626716901 hasAuthorship W2626716901A5066252006 @default.
• W2626716901 hasAuthorship W2626716901A5072414228 @default.
• W2626716901 hasAuthorship W2626716901A5079366973 @default.
• W2626716901 hasBestOaLocation W26267169012 @default.
• W2626716901 hasConcept C104317684 @default.
• W2626716901 hasConcept C126322002 @default.
• W2626716901 hasConcept C142462285 @default.
• W2626716901 hasConcept C151730666 @default.
• W2626716901 hasConcept C159110408 @default.
• W2626716901 hasConcept C162324750 @default.
• W2626716901 hasConcept C175444787 @default.
• W2626716901 hasConcept C185592680 @default.
• W2626716901 hasConcept C194828623 @default.
• W2626716901 hasConcept C27415008 @default.
• W2626716901 hasConcept C2777267654 @default.
• W2626716901 hasConcept C29122968 @default.
• W2626716901 hasConcept C3013748606 @default.
• W2626716901 hasConcept C31266012 @default.

• next